» Articles » PMID: 28830219

Optimization of Radiotherapy Fractionation Schedules Based on Radiobiological Functions

Overview
Journal Br J Radiol
Specialty Radiology
Date 2017 Aug 24
PMID 28830219
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To present a method for optimizing radiotherapy fractionation schedules using radiobiological tools and taking into account the patient´s dose-volume histograms (DVH).

Methods: This method uses a figure of merit based on the uncomplicated tumour control probability (P) and the generalized equivalent uniform dose (gEUD). A set of doses per fraction is selected in order to find the dose per fraction and the total dose, thus maximizing the figure of merit and leading to a biologically effective dose that is similar to the prescribed schedule.

Results: As a clinical example, a fractionation schedule for a prostate treatment plan is optimized and presented herein. From a prescription schedule of 70 Gy/35 × 2  Gy, the resulting optimal schema, using a figure of merit which only takes into account P, is 54.4 Gy/16 × 3.4  Gy. If the gEUD is included in that figure of merit, the result is 65 Gy/26 × 2.5  Gy. Alternative schedules, which include tumour control probability (TCP) and the normal tissue complication probability (NTCP) values are likewise shown. This allows us to compare different schedules instead of solely finding the optimal value, as other possible clinical factors must be taken into account to make the best decision for treatment.

Conclusion: The treatment schedule can be optimized for each patient through radiobiological analysis. The optimization process shown below offers physicians alternative schedules that meet the objectives of the prescribed radiotherapy. Advances in knowledge: This article provides a simple, radiobiological-function-based method to take advantage of a patient's dose-volume histograms in order to better select the most suitable treatment schedule.

Citing Articles

Exosomes Derived from Radioresistant Breast Cancer Cells Promote Therapeutic Resistance in Naïve Recipient Cells.

Payton C, Pang L, Gray M, Argyle D J Pers Med. 2021; 11(12).

PMID: 34945782 PMC: 8704086. DOI: 10.3390/jpm11121310.


Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.

Spohn S, Sachpazidis I, Wiehle R, Thomann B, Sigle A, Bronsert P Front Oncol. 2021; 11:652678.

PMID: 34055621 PMC: 8160377. DOI: 10.3389/fonc.2021.652678.


A Model-Based Method for Assessment of Salivary Gland and Planning Target Volume Dosimetry in Volumetric-Modulated Arc Therapy Planning on Head-and-Neck Cancer.

Zhang H, Cao Y, Antone J, Riegel A, Ghaly M, Potters L J Med Phys. 2019; 44(3):201-206.

PMID: 31576068 PMC: 6764180. DOI: 10.4103/jmp.JMP_19_19.


Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.

Lu J, Lin P, Huang B Radiat Oncol. 2019; 14(1):111.

PMID: 31221159 PMC: 6587287. DOI: 10.1186/s13014-019-1318-9.


The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.

van Leeuwen C, Oei A, Crezee J, Bel A, Franken N, Stalpers L Radiat Oncol. 2018; 13(1):96.

PMID: 29769103 PMC: 5956964. DOI: 10.1186/s13014-018-1040-z.

References
1.
Zhao B, Joiner M, Orton C, Burmeister J . "SABER": A new software tool for radiotherapy treatment plan evaluation. Med Phys. 2010; 37(11):5586-92. DOI: 10.1118/1.3497152. View

2.
Di Franco R, Borzillo V, Ravo V, Ametrano G, Falivene S, Cammarota F . Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis. Oncotarget. 2017; 8(10):17383-17395. PMC: 5370048. DOI: 10.18632/oncotarget.14798. View

3.
Hocht S, Aebersold D, Albrecht C, Bohmer D, Flentje M, Ganswindt U . Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2016; 193(1):1-12. PMC: 5203817. DOI: 10.1007/s00066-016-1041-5. View

4.
Brenner D, Hall E . Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999; 43(5):1095-101. DOI: 10.1016/s0360-3016(98)00438-6. View

5.
Kim M, Stewart R, Phillips M . A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization. Med Phys. 2015; 42(11):6671-8. DOI: 10.1118/1.4934369. View